Lignin-graft-PLGA drug-delivery system improves efficacy of MEK1/2 inhibitors in triple-negative breast cancer cell line

C. Ethan Byrne, Carlos E. Astete, Manibarathi Vaithiyanathan, Adam T. Melvin, Mahsa Moradipour, Stephen E. Rankin, Barbara L. Knutson, Cristina M. Sabliov, Elizabeth C. Martin

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Few targeted therapies are available for triple-negative breast cancer (TNBC) patients. Here, we propose a novel alkaline-lignin-conjugated-poly(lactic-co-glycolic acid) (L-PLGA) nanoparticle drug delivery system to improve the efficacy of targeted therapies. Materials & methods: L-PLGA nanoparticles (NPs) loaded with the MEK1/2 inhibitor GDC-0623 were characterized, tested in vitro on MDA-MB-231 TNBC cell line and compared with loaded PLGA NPs. Results: Loaded L-PLGA NPs were less than half the size of PLGA NPs, had slower drug release and improved the efficacy of GDC-0623 when tested in vitro. We demonstrated that GDC-0623 reversed epithelial-to-mesenchymal transition in TNBC. Conclusion: Our findings indicate that L-PLGA NPs are superior to PLGA NPs in delivering GDC-0623 to cancer cells for improved efficacy in vitro.

Original languageEnglish
Pages (from-to)981-1000
Number of pages20
JournalNanomedicine
Volume15
Issue number10
DOIs
StatePublished - Apr 2020

Bibliographical note

Publisher Copyright:
© 2020 © 2020 Future Medicine Ltd.

Keywords

  • breast cancer
  • drug delivery
  • lignin
  • nanoparticle
  • targeted therapies
  • triple-negative

ASJC Scopus subject areas

  • Bioengineering
  • Development
  • Biomedical Engineering
  • General Materials Science
  • Medicine (miscellaneous)

Fingerprint

Dive into the research topics of 'Lignin-graft-PLGA drug-delivery system improves efficacy of MEK1/2 inhibitors in triple-negative breast cancer cell line'. Together they form a unique fingerprint.

Cite this